Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: Canada Firm Raises New Medtech Seed Fund

12 Oct

A venture capital firm based in Toronto, Canada with an additional office in the USA invests in early stage start-ups across several industries including healthcare. The firm typically invests US$50-250K in seed-stage companies, while Series A or B may also be considered. The firm only follows in a financing round. The firm is currently looking for opportunities from North America.

Within healthcare, the firm takes an opportunistic approach and considers across medical devices, diagnostics, and healthcare IT. The firm is agnostic to disease indications. The firm prefers revenue-generating companies, while pre-revenue companies could also be considered. The firm will also consider some therapeutics opportunities depending on the lead.

The firm is looking for teams with a good mixture of technical expertise and business experience. The firm takes an active approach post-investment and seeks to work with passionate, talented entrepreneurs with strong academic track records.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com

Hot Investor Mandate 2: Transatlantic Investment Firm Looks for New Opportunities in Therapeutics, Diagnostics and Medical Devices

12 Oct

A venture capital firm with investment teams in the USA and Switzerland is currently investing out of their second fund, and looks to invest in early-stage life science companies crossing all sectors. The firm focuses on Seed, Series A and Series B investments. Investment is in the form of equity with the firm making roughly 3-5 new investments per year. The firm typically invests $500K – $5M per round (depending on the stage and needs of the company), and generally invests $10-$15M throughout the life of a company. The firm is very comfortable leading investment rounds, and focuses on companies in the US and Europe.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, tools and medical device sectors. The firm is opportunistic in terms of sub-sectors and indications. The firm is only interested in preclinical/Phase I, early-stage technology. The firm looks for companies with proprietary technologies that allow them to address unmet needs in a unique and compelling manner. The firm is not interested in healthcare IT, healthcare services or software companies.

The firm invests in privately-held companies with passionate founders and/or a strong management team. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com

Hot Investor Mandate 3: Innovation Fund Partners with Healthcare Organizations to Invest In Healthcare IT Companies

12 Oct

A firm focused on innovation innovation and entrepreneurship in healthcare works with dozens of leading healthcare organizations to advance an innovation strategy in order to drive sustainable impact. The firm manages a $35 million fund focused on health technologies with a provider angle. Typical size of an initial investment is $1-3 million in Seed to Series B round. The firm can invest up to $5 million over the lifetime of a company. The firm is open to leading or syndicating in a financing round. The firm is currently seeking opportunities globally, but currently has a focus in the U.S.

The firm considers HealthTech innovations that have a strategic angle to healthcare providers and do not need to go through regulatory development hurdle. Examples may include healthcare operational improvement, healthcare workflow management, data analytics, radiologic information analysis, telemedicine, population management, and automated screening. The firm is interested in the diseases that affect large populations such as oncology, cardiovascular diseases and stroke, hypertension, and geriatric conditions. The firm does consider devices if they are past the regulatory hurdle and can be applied to a large health system.

The firm is looking for competent management teams developing innovative solutions to real-world problems in the healthcare industry. The firm’s limited partner is actively involved in the vetting process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com

Hot Investor Mandate 4: China Investment Firm Dedicates $100 Million Fund to US Pharma and Medtech Opportunities

12 Oct

A China-based firm invests from a US$700M healthcare fund with an investment strategy focused on global growth opportunities. The company’s US offices have a US$100M VC fund focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through the fund is US$5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, health care IT and services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mailto:mandates@lifesciencenation.com

Hot Investor Mandate 1: Global Venture Firm Raises New Fund to Invest Opportunistically in Clinical Stage Life Science Companies

5 Oct

A venture capital firm with offices throughout the USA and Asia has recently closed its fifth fund of over $220M and is actively seeking investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in China and Southeast Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Europe-Based Fund Invests in Advanced Therapeutics

5 Oct

A London-based fund interested in advanced therapeutics invests in both private and public companies throughout the US, and Europe. For private deals, the firm makes equity deals in early-stage biotech therapeutic companies. The firm typically looks to make 8-10 deals in the private sector through each yearly cycle and typically allocates between $1M – $5M in each deal. The firm typically follows on these investments, preferring not to lead. The firm typically invests in seed and Series A rounds.

The firm is currently seeking biotech therapeutics that are considered advanced therapeutics. Examples of some therapies that the firm considers as advanced therapies are cell therapies and gene therapies. Currently, the firm is interested in immuno-oncology therapeutics, but is not interested in checkpoint inhibitors. For these therapeutics companies, they prefer that the asset is currently pre-clinical, in Phase I, or ready for phase II. The firm is agnostic in terms of specific indications.

The firm prefers investing in companies located in the European Union, but typically finds that a good amount of their deals are based in the United States. The firm is open to other geographies, but has yet to see a deal that is particularly interesting to them from other areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Russia-Based Pharma Seeks Oncology, Immunology, Infectious Disease & Diagnostic Assets Worldwide

5 Oct

A large pharmaceutical company based in Russia, with additional offices worldwide is actively seeking partnering and in-licensing opportunities across all developmental stages globally.

The firm’s partnering interests are primarily in the hospital care areas. The firm is looking for collaboration in oncology (in therapeutics and diagnostics), autoimmune/inflammatory diseases, novel antibacterial products and diagnostics (particularly in application to Gram-negative organisms), anti-viral, anti-fungal therapeutics, diagnostics for acute hospital care, rare/orphan disease areas, and cell therapies. The firm is seeking to in-license early-stage assets from pre-clinical to Phase I. However, with rare and orphan disease therapeutics, the company will prefer later-stage clinical assets.

The firm seeks to work with companies developing innovative therapeutics and management teams with strong scientific expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com